Literature DB >> 24948346

Current management of neonatal abstinence syndrome secondary to intrauterine opioid exposure.

Jason R Wiles1, Barbara Isemann2, Laura P Ward3, Alexander A Vinks4, Henry Akinbi5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24948346      PMCID： PMC4144410          DOI： 10.1016/j.jpeds.2014.05.010

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


× No keyword cloud information.
  54 in total

1.  Neonatal abstinence syndrome: assessment and management.

Authors:  L P Finnegan; J F Connaughton; R E Kron; J P Emich
Journal:  Addict Dis       Date:  1975

2.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

3.  Neonatal drug withdrawal. American Academy of Pediatrics Committee on Drugs.

Authors: 
Journal:  Pediatrics       Date:  1998-06       Impact factor: 7.124

Review 4.  The impact of prenatal drug exposure on the neonate.

Authors:  C L Wagner; L D Katikaneni; T H Cox; R M Ryan
Journal:  Obstet Gynecol Clin North Am       Date:  1998-03       Impact factor: 2.844

5.  Neonatal abstinence syndrome after methadone or buprenorphine exposure.

Authors:  Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer
Journal:  N Engl J Med       Date:  2010-12-09       Impact factor: 91.245

6.  Neonatal abstinence syndrome and associated health care expenditures: United States, 2000-2009.

Authors:  Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis
Journal:  JAMA       Date:  2012-04-30       Impact factor: 56.272

Review 7.  Pharmacologic management of the opioid neonatal abstinence syndrome.

Authors:  Walter K Kraft; John N van den Anker
Journal:  Pediatr Clin North Am       Date:  2012-08-30       Impact factor: 3.278

8.  Sublingual buprenorphine for treatment of neonatal abstinence syndrome: a randomized trial.

Authors:  Walter K Kraft; Eric Gibson; Kevin Dysart; Vidula S Damle; Jennifer L Larusso; Jay S Greenspan; David E Moody; Karol Kaltenbach; Michelle E Ehrlich
Journal:  Pediatrics       Date:  2008-08-11       Impact factor: 7.124

9.  Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions.

Authors:  D A Barrett; D P Barker; N Rutter; M Pawula; P N Shaw
Journal:  Br J Clin Pharmacol       Date:  1996-06       Impact factor: 4.335

10.  Increasing prevalence of neonatal withdrawal syndrome: population study of maternal factors and child protection involvement.

Authors:  Melissa O'Donnell; Natasha Nassar; Helen Leonard; Ronnie Hagan; Richard Mathews; Yvonne Patterson; Fiona Stanley
Journal:  Pediatrics       Date:  2009-04       Impact factor: 7.124
View more
  9 in total

1.  Methadone dosing strategies in preterm neonates can be simplified.

Authors:  Tamara van Donge; Samira Samiee-Zafarghandy; Marc Pfister; Gilbert Koch; Majid Kalani; Arash Bordbar; John van den Anker
Journal:  Br J Clin Pharmacol       Date:  2019-04-10       Impact factor: 4.335

2.  Evaluation of the Cardiovascular Effects of Clonidine in Neonates Treated for Neonatal Abstinence Syndrome.

Authors:  Raymond P Meddock; Deirdre Bloemer
Journal:  J Pediatr Pharmacol Ther       Date:  2018 Nov-Dec

3.  The development of a high-performance liquid chromatography-tandem mass spectrometric method for simultaneous quantification of morphine, morphine-3-β-glucuronide, morphine-6-β-glucuronide, hydromorphone, and normorphine in serum.

Authors:  David Sartori; Tamorah Lewis; Autumn Breaud; William Clarke
Journal:  Clin Biochem       Date:  2015-06-26       Impact factor: 3.281

4.  Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study.

Authors:  Jason R Wiles; Barbara Isemann; Tomoyuki Mizuno; Meredith E Tabangin; Laura P Ward; Henry Akinbi; Alexander A Vinks
Journal:  J Pediatr       Date:  2015-09-11       Impact factor: 4.406

Review 5.  Modeling prenatal opioid exposure in animals: Current findings and future directions.

Authors:  Elizabeth M Byrnes; Fair M Vassoler
Journal:  Front Neuroendocrinol       Date:  2017-09-28       Impact factor: 8.606

6.  Treatment of opioid withdrawal in neonates with morphine, phenobarbital, or chlorpromazine: a randomized double-blind trial.

Authors:  Urs Zimmermann; Christoph Rudin; Angelo Duò; Leonhard Held; Hans Ulrich Bucher
Journal:  Eur J Pediatr       Date:  2019-11-06       Impact factor: 3.183

7.  Buprenorphine pharmacotherapy for the management of neonatal abstinence syndrome in methadone-exposed neonates.

Authors:  Afshin A Taleghani; Barbara T Isemann; Ward R Rice; Laura P Ward; Kathy E Wedig; Henry T Akinbi
Journal:  Paediatr Neonatal Pain       Date:  2019-11-01

8.  Ontogenetic Oxycodone Exposure Affects Early Life Communicative Behaviors, Sensorimotor Reflexes, and Weight Trajectory in Mice.

Authors:  Elena Minakova; Simona Sarafinovska; Marwa O Mikati; Kia M Barclay; Katherine B McCullough; Joseph D Dougherty; Ream Al-Hasani; Susan E Maloney
Journal:  Front Behav Neurosci       Date:  2021-02-22       Impact factor: 3.617

Review 9.  Clinical pharmacology and dosing regimen optimization of neonatal opioid withdrawal syndrome treatments.

Authors:  Fei Tang; Chee M Ng; Henrietta S Bada; Markos Leggas
Journal:  Clin Transl Sci       Date:  2021-05-01       Impact factor: 4.689
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.